Eisai Co., Ltd. (ESALF)

OTCMKTS · Delayed Price · Currency is USD

29.00

+1.24 (4.47%)

Aug 1, 2025, 12:38 PM EDT

Eisai Employees

Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.

Employees

10,917

Change (1Y)

-150

Growth (1Y)

-1.36%

Revenue / Employee

$482,873

Profits / Employee

$28,402

Market Cap

8.09B

Employees Chart

Employees History

Date	Employees	Change	Growth
Mar 31, 2025	10,917	-150	-1.36%
Mar 31, 2024	11,067	-9	-0.08%
Mar 31, 2023	11,076	-246	-2.17%
Mar 31, 2022	11,322	85	0.76%
Mar 31, 2021	11,237	239	2.17%
Mar 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Mar 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Mar 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Mar 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Mar 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
Endo, Inc.	3,116
Tian'an Technology Group	8
Elite Pharmaceuticals	68
Glass House Brands	374
Northwest Biotherapeutics	25
CytoDyn	9
American Oncology Network	1,914
Silence Therapeutics	116

Employee Rankings

Eisai News

2 days ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
19 days ago - "URECE" (Dotinurad) Launched in China as a treatment for Gout - Benzinga
7 weeks ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
2 months ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
2 months ago - Eisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
2 months ago - Eisai GAAP EPS of ¥163.76, revenue of ¥789.4B; initiates FY outlook - Seeking Alpha
3 months ago - Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
3 months ago - Biogen/ Eisai win EU approval for Alzheimer’s therapy - Seeking Alpha